Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bextra "not approvable" for migraine

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Pfizer's COX-2 inhibitor Bextra (valdecoxib) is "not approvable" for treatment of migraine as of August, Pfizer's Nov. 5 10-Q filing with the Securities & Exchange Commission states. Bextra faces another setback with the expected addition of a "black box" warning to labeling regarding skin reactions. "Revised labeling for the product…will likely include the addition of a black box," the SEC filing says. The firm's Oct. 15 "Dear Doctor" letter also includes a discussion of Bextra's cardiovascular safety profile. Data showing an apparent increased risk in CV events in two studies in high-risk surgery patients were presented at the American Heart Association meeting Nov. 9...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002694

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel